Browse studies

Find your next paid study

16 recruiting studies matching your filters

Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that…

Recurrent Langerhans Cell HistiocytosisRefractory Langerhans Cell Histiocytosis

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05828069

Phase 2

A Phase II Trial of the MEK Inhibitor Mirdametinib in Histiocytic Disorders

The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be …

Langerhans Cell Histiocytosis (LCH)Juvenile Xanthogranuloma (JXG)Rosai-Dorfman Disease (RDD)+1 more

Estimated

~$10 – $5,625

Children's Hospital Medical Center, CincinnatiNCT06153173

Phase 1

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more

Estimated

~$10 – $7,500

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, whic…

Lymphohistiocytosis, HemophagocyticSecondary Hemophagocytic LymphohistiocytosisMacrophage Activation Syndrome+1 more

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT06339177

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patien…

Adrenal Gland PheochromocytomaCarcinoma In SituCentral Nervous System Neoplasm+15 more

Estimated

~$10 – $1,125

Children's Oncology GroupNCT02402244

Phase 1

Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

This is a pilot study to gather information about safety and efficacy of using ruxolitinib (RUX) to treat Immune Effector Cell Associated Hemophagocytic Lympho…

Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)

Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07424222

Phase 1

Pilot Study of Pre-emptive Anakinra for the Prevention of Severe Cytokine Release Syndrome in Children and Young Adults With B-Acute Lymphoblastic Leukemia Receiving Chimeric Antigen Receptor (CAR) T Cells

Objectives: The primary objective of this study will be to evaluate the impact of pre-emptive use of anakinra on the rate of severe cytokine release syndrome (…

B-Acute Lymphoblastic LeukemiaCAR-T Cell TherapyCytokine Release Syndrome+2 more

Estimated

~$10 – $7,500

Kevin McNerneyNCT06703216

Phase 2

A Phase II Prospective Study Evaluating Selective Depletion of CD45RA+ (Naïve) T Cells (TND) From Peripheral Blood Stem Cell (PBSC) Grafts for Prevention of Graft Versus Host Disease (GVHD) in Non-Malignant Diseases (NMDs)

This phase II trial investigates how well a naive T cell depleted graft work for the reduction of graft versus host disease in patients with non-malignant dise…

Bone Marrow FailureHemoglobinopathiesPrimary Immune Deficiency (PID)+4 more

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT07660783

Histiocytic Disorder Follow-up Study

The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-…

HistiocytosisLangerhans Cell HistiocytosisErdheim-Chester Disease+3 more

Estimated

~$10 – $750

University of Alabama at BirminghamNCT05915208

Phase 2

A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocyt…

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Estimated

~$10 – $8,750

Electra Therapeutics Inc.NCT05416307

Phase 3

Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115)

Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell hist…

Langerhans Cell Histiocytosis

Estimated

~$10 – $6,250

Baylor College of MedicineNCT02670707

Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, …

Rare DisordersUndiagnosed DisordersDisorders of Unknown Prevalence+340 more